The dose range is 1.6-4.8 mg per injection: The standard KLOW dose is 3.2 mg total per injection: 2 mg GHK-Cu plus 0.4 mg each of BPC-157, TB-4, and KPV The low-end of the dose range is 1.6 mg, anchored on 1 mg of GHK-Cu with 200 mcg each of BPC-157, TB-4, and KPV The high-end of the dose range is 4.8 mg, anchored on 3 mg of GHK-Cu with 600 mcg each of BPC-157, TB-4, and KPV There is no trial-established dose for KLOW the dose range is mechanistically derived from a combination of each peptide
Accounts for up to 30% of reported 'non-responder' cases in peptide research protocols
It is being studied in diabetic neuropathy (NERVARA Phase 2 trial), sarcoidosis, and ischemic injury models
Influence of intranasal drugs on human nasal mucociliary clearance and ciliary beat frequency
FOXO4-DRI Peptide and Hypogonadism A study (4) was conducted to explore the potential of FOXO4-DRI peptide in age-related male late-onset hypogonadism